VivoSeq
Other

Inflammatory Response

57

Pipeline Programs↗

18

Active Trials↗

28

Companies Involved↗

Inflammatory Response is a moderately active landscape with 57 programs across 28 companies. The most active players are Boehringer Ingelheim, Aristea Therapeutics, Inc., Bayer. 18 therapies are approved with 4 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

63/100

Pipeline Velocity

22/100

Mech. Concentration

17/100

Completion Rate

83/100

Attrition Rate

10/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Boehringer Ingelheim logo

Boehringer Ingelheim

5 programs

Phase 1A

Aristea Therapeutics, Inc.

1 program

Phase 1Bayer logo

Bayer

1 program

Phase 1M

Milestone Pharmaceuticals Inc.

1 program

Phase 1Biogen logo

Biogen

1 program

Phase 1GSK logo

GSK

2 programs

Phase 1

Pipeline

Programs by Phase

Preclinical20

Methotrexate

Alnylam Pharmaceuticals

Celecoxib

Philadelphia Eye Associates

Fentanyl

Cephalon

Hydrocortisone

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Infliximab

Organon and Co

Phase 18

Aspirin

Bayer

Lipopolysaccharide

Boehringer Ingelheim

Natalizumab

Biogen

Prednisolone Low

Boehringer Ingelheim

RIST4721

Aristea Therapeutics, Inc.

Phase 27

Dexmedetomidine

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Ketamine

Aultman Health Foundation

Etoricoxib

Novartis

Levobupivacaine

Purdue Pharma LP

Recombinant Human Plasma Gelsolin

BioAegis Therapeutics Inc.

Phase 34

Dexamethasone

Aspen Global Incorporated

Tranexamic Acid

Amring

Systemic Proteolytic Enzyme (tibrolin)

University of Baghdad

Colchicine Po

Ottawa Hospital Research Institute

Approved18

Methylprednisolone

Pfizer

Propofol

Fresenius Kabi Oncology Ltd.

Midazolam

Conrado Roberto Hoffmann Filho

Morphine

Hikma Pharmaceuticals LLC

Ibuprofen

Kenvue Brands

Analysis

Modality Breakdown

95%

Small molecule

69 of 73 classified programs — the dominant modality here.

5%ALL OTHERSMonoclonal antibody23%Vaccine23%

Small molecule leads; the ring shows all 73 classified programs, each share of the total. Modality classified for 100% of 81 pipeline programs.

Analysis

Trial Status

78

clinical trials

Completed40 · 51%
Unknown status12 · 15%
Recruiting11 · 14%
Terminated7 · 9%
Not yet recruiting4 · 5%
Active, not recruiting3 · 4%
Other1 · 1%

Clinical Trials

Trial Activity

78 trials

Deciphering IL-17-dependant Inflammatory Response in Bullous Pemphigoid
Recruiting·CCHU de Reims·N/A·NCT06479018·140 enrolled
Evaluation of the Effect of Systemic Proteolytic Enzyme Therapy on Postoperative Inflammatory Response and QoL After Surgical Extraction of Impacted Mandibular Third Molars
Recruiting·UUniversity of Baghdad·Phase 3·NCT05681312·55 enrolled
"Effect of Ibuprofen on Acute Inflammatory Response After One-Stage Periodontal Therapy"
Recruiting·UUniversity of Baghdad·Phase 4·NCT07459049·30 enrolled
Effect of Methylprednisolone on Systemic Inflammatory Response During Pediatric Congenital Open-Heart Surgery
Recruiting·—·Phase 4·NCT05927233·60 enrolled
Effect of infLuenza vaccInation After Myocardial INfArction on Cardiac inflammaTory responsE
Recruiting·—·Phase 4·NCT06336317·90 enrolled
Protective Effect of CoQ10 Against Negative Inflammatory Response and Organ Dysfunction in Cardiovascular Surgery (PANDA V)
Recruiting·NNanjing Medical University·N/A·NCT04444349·500 enrolled
The Effect of Dexamethasone Administration Route and Local Anesthetic Concentration on Pain, Inflammatory Response, and Neuromonitoring in Children Undergoing Scoliosis Correction
Recruiting·PPoznan University of Medical Sciences·Phase 4·NCT06789029·60 enrolled
Early Tranexamic Acid and Modulating the Inflammatory Response in Sepsis
Recruiting·—·Phase 3·NCT04910464·80 enrolled
Cerebral and Anti-inflammatory Response Through Exercise - Mechanisms In Depressive Disorders
Recruiting·FFundación de Investigación Biomédica - Hospital Universitario de La Princesa·N/A·NCT06450704·124 enrolled
Colchicine to Quench the Inflammatory Response After Deep Vein Thrombosis (The Conquer-DVT Pilot Trial)
Recruiting·OOttawa Hospital Research Institute·Phase 3·NCT06440694·150 enrolled
Effects of Dexmedetomidine Versus Ketamine on Inflammatory Response and Hemodynamic in Patients
Recruiting·NNew Valley University·Phase 1/2·NCT06490731·2 enrolled
The Role of the Adrenergic System in Hypoglycaemia Induced Inflammatory Response in People With Type 1 Diabetes and People Without Type 1 Diabetes-RAID-II
Active, not recruiting·RRadboud University Medical Center·N/A·NCT06422494·24 enrolled
Pain Control in Breast Surgery: Analgesia, Opioid Consumption and Inflammatory Response Evaluation
Active, not recruiting·HHospital Sirio-Libanes·N/A·NCT02647385·50 enrolled
Rhu-pGSN to Mitigate Proinflammatory Responses to Decompression in Healthy SCUBA Divers
Active, not recruiting·BBioAegis Therapeutics Inc.·Phase 2·NCT06216366·36 enrolled
Immuno-inflammatory Response of Erdosteine in COPD
Not yet recruiting·—·N/A·NCT07329946·30 enrolled
Page 1 of 6

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)